Protein Biosynthesis Interference in Disease
- 1st Edition - October 8, 2020
- Imprint: Academic Press
- Author: Elena L. Paley
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 4 8 5 - 3
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 3 4 8 6 - 0
Protein Biosynthesis Interference in Disease offers a thorough discussion and overview of protein biosynthesis interference, its mechanisms of action, and influence over diseas… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteProtein Biosynthesis Interference in Disease offers a thorough discussion and overview of protein biosynthesis interference, its mechanisms of action, and influence over disease processes. This book examines the role of protein biosynthesis interference in Alzheimer’s and other neurodegenerative conditions, cancer and inflammatory disorders, with specific attention paid to the biochemical dynamics of tryptamine, biogenic amines and aminoacyl-tRNA synthetases in these pathologies. Methods of regulating protein translation and interference mechanisms, including gene therapy, are presented, empowering biochemists, molecular biologists, disease researchers, and health professionals to understand the underlying factors of protein disease and improve patient outcomes.
- Enables biochemists, molecular biologists and disease researchers to advance disease prevention, laboratory testing, and treatment pathways for protein biosynthesis interference related disorders
- Examines the biochemical and molecular basis of protein biosynthesis interference in neurodegenerative disorders, cancer and inflammatory conditions, among other diseases
- Analyzes tryptamine, biogenic amines, and aminoacyl-tRNA synthetases dynamics in protein translation and possible treatment pathways regulating protein biosynthesis
Active researchers and students of biochemistry, molecular biology, cellular biology, neuroscience, protein biochemistry, and nutrition. Clinicians and students of life science and medicine
- Cover image
- Title page
- Table of Contents
- Copyright
- Preface
- Chapter 1. Introduction
- Abstract
- Chapter 2. Tryptamine in the diet, human microbiome, tRNA aminoacylation-protein biosynthesis, host-microbiota metabolic interactions
- Abstract
- 2.1 Tryptamine interfere with the tRNA aminoacylation-protein biosynthesis in the model of neurodegeneration
- 2.2 Tryptamine interfere with serotonin binding to receptors in serotonin syndrome
- 2.3 Tryptamine in dysbiosis
- Chapter 3. Dimethyltryptamine, methyltryptamine, hallucinations and metals
- Abstract
- Chapter 4. Psychoactive effects and toxicity of tryptamine, N-methyltryptamine (NMT), and N, N-dimethyltryptamine (DMT): quantification methods
- Abstract
- Chapter 5. Tryptamine in renal pathologies and in pregnancy
- Abstract
- Chapter 6. Tryptophanyl-tRNA synthetase (TrpRS) inhibition or TrpRS gene (WARS) mutations and deletion result to TrpRS deficiency and pathologies
- Abstract
- Chapter 7. Tryptamine in liver diseases and alcohol abuse
- Abstract
- Chapter 8. Tryptamine and tyramine in tobacco smoking
- Abstract
- Chapter 9. Tryptamine and other biogenic amines in human vaginal samples
- Abstract
- Chapter 10. Tryptamine and tryptophan in human fecal samples: diet alters tryptamine levels
- Abstract
- Chapter 11. Tryptamine in human noncataractous and cataractous eye lenses
- Abstract
- Chapter 12. Tryptamine toxicity in rats, adrenalectomy, toxicity prevention
- Abstract
- Chapter 13. Microorganisms: the natural producers of tryptamine in food
- Abstract
- Chapter 14. Human gut bacterial sequence associated with Alzheimer’s disease and biogenic amines
- Abstract
- Chapter 15. Diseases, factors and conditions associated with Alzheimer’s disease (AD) and dementia support a concept that AD is a widespread systemic disorder
- Abstract
- 15.1 Historical evolution and terminology from 1907 to contemporary
- 15.2 Senile plaques and neurofibrillary tangles in organs other than brain
- 15.3 Diseases, factors and conditions associated with Alzheimer’s disease and dementia
- Chapter 16. Arterial hypertension is comorbidity in dementia and Alzheimer’s disease, tryptamine in metabolic syndrome
- Abstract
- Chapter 17. Whole blood viscosity: biogenic amines, dementia and Alzheimer’s disease
- Abstract
- Chapter 18. Tryptamine and aminoacyl-tRNAs in sleep–wake and circadian disruption
- Abstract
- Chapter 19. Senile plaques and/or neurofibrillary tangles in brain of non-demented individuals
- Abstract
- Chapter 20. Historical perspective and future research directions
- Abstract
- 20.1 On determining the most appropriate test cut-off values for Alzheimer’s disease associated sequence (ADAS)-linked tryptamine and other biogenic amines in human samples
- 20.2 Updated hypothesis of tryptamine-induced neurodegeneration: experimental and observational data
- 20.3 Validation studies and future experiments
- 20.4 Major challenges for new preclinical and clinical trials
- 20.5 Tryptamine physiological pathways: tryptamine is a ligand and agonist activating 5H, TAAR1, and AhR receptors
- 20.6 Linkage of present theory to other theories and the major pathological features of Alzheimer’s disease
- Chapter 21. Tryptamine content and effects in human and animals
- Abstract
- 21.1 Tryptamine µg-mg/g contents in humans and in animals, and effects of food supplementation
- 21.2 Effects of tryptamine administrations to humans and animals
- 21.3 Biogenic amine substrate inhibition of enzymes metabolizing biogenic amines
- 21.4 Cardiac and blood vessel effects of biogenic amines, genistein and other dietary monoamine oxidase inhibitors
- 21.5 Membrane-bound organic cation tryptamine in humans and mammalian animals
- 21.6 Tryptamine and other biogenic amines: oxidative stress and mitosis
- Chapter 22. Link of protein half-lives to neurodegeneration: tryptamine treatment effects
- Abstract
- Chapter 23. Alzheimer’s disease human gut microbiome associated sequence (ADAS): predictive disease modeling with ADAS: generating ADAS variants from human samples
- Abstract
- 23.1 ADAS in colorectal cancer: relation to gender and race
- 23.2 ADAS in healthy human subjects: young Japanese versus age-matched American and senior Chinese individuals
- 23.3 Usage of antibiotics and MAOI: links to ADAS, colorectal cancer and cognitive dysfunction
- 23.4 ADAS in development of diseases in aging: aged male health professionals (HPFS) vs young males and age-matched individuals (healthy controls and CRC patients)
- 23.5 Histamine-mediated inflammation associated with Alzheimer’s disease and linked conditions: dysbiosis, metabolic syndrome, diabetes, obesity and ADAS occurrence; regulation of immune response by histamine
- Chapter 24. Tryptamine and other biogenic amines (BA) as modifiable and degradable factors
- Abstract
- 24.1 Factors affecting tryptamine and BA contents
- 24.2 Conclusion
- 24.3 Recommendations
- Chapter 25. Tryptamine and TrpRS in cancer and other conditions
- Abstract
- 25.1 Tryptamine-TrpRS interplay, tryptamine in cancer metabolomics
- 25.2 Tryptophanyl-tRNA synthetase in cancer
- 25.3 TrpRS expression in other conditions
- 25.4 TrpRS in viral infections
- 25.5 TrpRS in bacterial infections
- 25.6 TrpRS in infections with protozoan, nematode parasites and pathogenic yeast
- 25.7 TrpRS binding to ligands and proteins
- 25.8 TrpRS overexpression in bovine/calf pancreas and antigenicity
- Chapter 26. Experimental procedures: tryptophanyl-tRNA synthetase (TrpRS) characterization
- Abstract
- 26.1 Human serum samples
- 26.2 Purification of bovine pancreas tryptophanyl-tRNA synthetase (bTrpRS)
- 26.3 Rabbit antisera, immunoglobulin G and polyclonal antibodies to bTrpRS
- 26.4 Casein isolation
- 26.5 Immunoprecipitation of bTrpRS following by immune complex protein kinase activity testing
- 26.6 Two-dimensional phosphoamino acid analysis and phosphopeptide mapping
- 26.7 Two-dimensional isofocusing-SDS gel electrophoresis and immunoblotting
- 26.8 Mass spectrometry analysis
- 26.9 Two-dimensional endogenous cleavage
- 26.10 Activity of purified bTrpRS in [γ32P]ATP-PPi exchange on TLC PEI cellulose
- Chapter 27. Tryptophanyl-tRNA synthetase (TrpRS) in phosphosignaling
- Abstract
- 27.1 Extracellular stimuli alter TrpRS phosphorylation
- 27.2 Phosphopeptide and phosphoamino acid analyses of TrpRS
- 27.3 Phosphorylation of bTrpRS isoelectric point isoforms
- 27.4 TrpRS phosphoisoforms assigned by mass spectrometry of Coomassie blue stained spots
- 27.5 Discovery of new TrpRS interactome using mass spectrometry
- 27.6 In-gel endogenous cleavage of TrpRS
- 27.7 Extracellular TrpRS deposits in Alzheimer’s disease blood vessels
- 27.8 TrpRS site-specific phosphorylation profiling
- Chapter 28. Tryptophanyl-tRNA synthetase antigenic epitopes and mimotopes
- Abstract
- Chapter 29. Interactomes: tryptophanyl-tRNA synthetase forms and other aminoacyl-tRNA synthetases
- Abstract
- 29.1 TrpRS interactome: purine nucleoside phosphorylase
- 29.2 TrpRS interactome: Rab GDP dissociation inhibitor 1
- 29.3 TrpRS interactome: vitamin D–binding protein (DBP) also known as gc-globulin
- 29.4 Interactions of TrpRS and tryptamine with hemoglobin-β complex, histones, albumin, lipocalin
- 29.5 Aminoacyl-tRNA synthetases in interactomes
- Chapter 30. Tryptophanyl-tRNA synthetase in cell and organism survival
- Abstract
- Chapter 31. Tryptophanyl-tRNA synthetase sharing epitopes
- Abstract
- 31.1 Cow’s milk-derived TrpRS in human immune crossreactivity
- 31.2 TrpRS of microbes and parasites: sharing epitopes and autoimmune response in humans
- Chapter 32. Tryptamine and tryptophanyl-tRNA synthetase in microvesicles, multivasicular bodies, and exosomes
- Abstract
- Chapter 33. Tryptophanyl-tRNA synthetase and tryptamine in protein kinase and cancer pathways
- Abstract
- 33.1 Tryptophanyl-tRNA synthetase expression and activity
- 33.2 Protein kinases toward tryptophanyl-tRNA synthetase phosphosites in phosphoproteomics
- Chapter 34. Global protein biosynthesis and aminoacyl-tRNA synthetase family
- Abstract
- 34.1 Tumorigenesis
- 34.2 Altered protein biosynthesis in Alzheimer’s disease
- 34.3 Conclusion
- References
- Index
- Edition: 1
- Published: October 8, 2020
- No. of pages (Paperback): 296
- No. of pages (eBook): 296
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128234853
- eBook ISBN: 9780128234860
EP
Elena L. Paley
Dr. Paley is Cofounder of the nonprofit Stop Alzheimers Corp and Founder of Expert Biomed, Inc. She holds a PhD degree in biology with specialization in molecular biology from the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences in the Laboratory of Lev L. Kisselev. Dr. Paley’s research focuses mainly on protein biosynthesis in biology and diseases and is conducted in collaboration with Harvard University, Brandeis University, the University of Miami, Tel Aviv University, the Institut des Vaisseaux et du Sang (Paris, France), and the University of Texas at San Antonio. She is Adjunct Professor at Nova Southeastern University, FL, United States, and is inventor in patents issued and pending. Dr. Paley has previously published 4 books with Elsevier.
Affiliations and expertise
Adjunct Professor at Nova Southeastern University, FL,, USARead Protein Biosynthesis Interference in Disease on ScienceDirect